Fig1. Expression of PD-1 in the activated spleen lymphocytes of homozygous humanized PD-1 BALB/c KI mice is detected by FACS.

Fig2.?Detection of hPD-1 expression on B cells, T cells and NKs in Bone Marrow in hPD-1 KI mice.

Fig3. In vivo validation of homozygous BALB/c-hPD1 mice. The homozygous BALB/c-hPD1 mice were inoculated with CT26 cells, and randomly assigned to different groups (n=7) when the tumor grew to a volume of 100 mm3. A combinatorial treatment of anti-hPD1 antibody Keytruda? and entinostat (ENT; a class I HDAC inhibitor) demonstrated a noticeable efficacy improvement compared to the same dose of single agent (A) without affecting the animal body weight (B).

Fig7. In vivo validation of homozygous BALB/c-hPD1 mice. The homozygous BALB/c-hPD1 mice were inoculated with CT26 cells, and randomly assigned to different groups (n=6) when the tumor grew to a volume of 65 mm3. A combinatorial treatment of anti-hPD1 antibody Opdivo? and anti-mCTLA antibody demonstrated a noticeable efficacy improvement compared to the same dose of single agent (A) without affecting the animal body weight (B). (In collaboration with Crownbio)